Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFlowtech Fluid. Regulatory News (FLO)

Share Price Information for Flowtech Fluid. (FLO)

Share Price is delayed by 15 minutes
Get Live Data
61.00    2.00 (3.39%)
Bid:
57.20
Ask:
61.00
Spread: 3.80 (6.643%)
Market Cap: £49.68m
FLO Live PriceLast checked at - London Stock Exchange

Intraday Flowtech Fluid. Share Chart

Offer Update

25 Jun 2008 16:10

RNS Number : 5450X
Mentor Graphics Corporation
25 June 2008
Β 

ο»Ώ

Not for release, publication or distribution, in whole or in part, in, into or from theΒ United States,Β Canada,Β AustraliaΒ or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

ANNOUNCEMENT

FOR IMMEDIATE RELEASE

25Β JuneΒ 2008

CASHΒ OFFERΒ FORΒ FLOMERICSΒ GROUP PLCΒ ("FLOMERICS" OR THE "COMPANY") BYΒ MENTOR GRAPHICS CORPORATIONΒ ("MENTOR")

Β 

AUTODESK DECLINES TO BID FOR FLOMERICS

The Board of MentorΒ notes the announcement from Flomerics in which itΒ confirmsΒ that Autodesk has declined to make an offer for Flomerics.

MentorΒ continues to believe that its cash offerΒ represents a highly attractive proposal to Flomerics Shareholders.Β MentorΒ acquiredΒ aΒ substantial number of shares from institutional investors at 104 pence per shareΒ andΒ also acquired 20.1 per cent. of Flomerics share capital from Pricap, a sophisticatedΒ financial institution active in this market.

As announced byΒ MentorΒ on 24 June 2008, the Offer is open forΒ acceptance until the next closing date, whichΒ isΒ 3.00 pm on 2 July 2008Β andΒ MentorΒ encourages Flomerics Shareholders to accept the Offer prior to this time.Β 

Mentor Graphics said: "Throughout this bid we have consistently urged shareholders not to be distracted by the possibility of anotherΒ bid which may or may not materialise. Our offerΒ remains the only one on the table andΒ delivers excellentΒ value to Flomerics shareholders. BeforeΒ MentorΒ started building its stake Flomerics was trading at 50.5p."Β 

Enquiries:

Mentor

RyersonΒ Schwark Tel: +1 503 685 7000

CenkosΒ SecuritiesΒ plcΒ 

Nicholas WellsΒ  Tel: +44Β 20Β 7397 8900

BellΒ Pottinger Corporate & Financial

David Rydell

Olly Scott Tel: +44Β 20 7861 3232

Terms used in this announcement shall have the meaning given to them in the full offer document sent to Flomerics Shareholders on 17 May 2008.

Cenkos, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Mentor and no one else in connection with the Offer and will not be responsible to anyone other than Mentor for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

Canaccord, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting exclusively for Mentor and no one else in connection with the Offer and will not beΒ responsible to anyone other than Mentor for providing the protections afforded to its customers or for providing advice in relation to the Offer or in relation to the contents of this announcement or any transaction or arrangement referred to herein.

This announcement is not intended to and does not constitute, or form any part of, an offer or an invitation to purchase, subscribe for or otherwise acquire, sell or dispose of any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Offer or otherwise. The OfferΒ isΒ made solely through the Offer Document and the Form of Acceptance, which together contain the full terms and conditions of the Offer, including details of how to accept the Offer. Any acceptance or other response to the Offer should be made only on the basis of the information contained in the Offer Document and the Form of Acceptance. The laws of relevant jurisdictions may affect the availability of the Offer to persons not resident in theΒ United Kingdom. Persons who are not resident in theΒ United Kingdom, or who are subject to the laws of any jurisdiction other than theΒ United Kingdom, should inform themselves about and observe any applicable legal and regulatory requirements. The Offer DocumentΒ isΒ available for public inspection at the offices of Cenkos.Β 

The OfferΒ isΒ not beingΒ made, directly or indirectly, in or into the United States or by use of mails of, or any means or instrumentality (including, without limitation, facsimile transmission, telephone or internet) of inter-state or foreign commerce of, or any facilities of a national, state or other securities exchange of the United States, norΒ isΒ it beingΒ made directly or indirectly in or into Canada or Australia and the OfferΒ isΒ not capable of acceptance by any such use, means, instrumentality or facilities or from within the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction. Accordingly, copies of this announcement are not being, will not be and must not be mailed or otherwise forwarded, distributed or sent in, into or from the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction and persons receiving this announcement (including without limitation custodians, nominees and trustees) must not mail, or otherwise forward, distribute or send it in, into or from the United States, Canada or Australia or any other such jurisdiction if to do so would constitute a violation of the relevant laws of such jurisdiction.

Cautionary statement regarding forward-looking statements

This announcement may contain forward-looking statements concerningΒ Mentor. Generally the words 'will', 'may', 'should', 'continue', 'believes', 'expects', 'intends', 'anticipates' or similar expressions identify forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those suggested by them. Many of these risks and uncertainties relate to factors that are beyondΒ Mentor's abilities to control or estimate precisely, such as future market conditions and the behaviours of other market participants, and therefore undue reliance should not be placed on such statements which speak only as at the date of this announcement. MentorΒ assumes no obligation and does not intend to update these forward-looking statements, except as required pursuant to applicable law.

Dealing disclosure requirements

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 'City Code'), if any person is, or becomes, 'interested' (directly or indirectly) in one per cent. or more of any class of 'relevant securities' of Flomerics, all 'dealings' in any 'relevant securities' of Flomerics (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30 pm (London time) on the London Business Day following the date of the relevant transaction. This requirement will continue until the date on which the Offer becomes, or is declared, unconditional as to acceptance, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of Flomerics they will be deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the City Code, all 'dealings' in 'relevant securities' of Flomerics by Mentor or Flomerics or by any of their respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London Business Day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Panel's website at www.thetakeoverpanel.org.uk.

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
OUPFKPKKPBKDPAB
Date   Source Headline
3rd Jun 20087:00 amRNSOffer Update
2nd Jun 20087:00 amRNSStatement re Unsolicited Offe
30th May 20084:40 pmRNSOffer Update
30th May 20082:36 pmRNSRule 2.10 Announcement
30th May 20089:30 amRNSAdditional Listing
29th May 20081:41 pmRNSResult of AGM
28th May 20082:15 pmRNSResult of AGM
28th May 20082:11 pmRNSPosting of Defence Document
28th May 20087:00 amRNSOffer Update
27th May 20087:00 amRNSQ1 Trading Update
19th May 20081:30 pmRNSStatement
19th May 20087:00 amRNSOffer Document Posted
16th May 20087:00 amRNSAnnual General Meeting
13th May 20081:20 pmRNSRule 8.3-Flomerics Plc
13th May 200812:45 pmRNSRule 8.3- Flomerics Group Plc
13th May 20089:35 amRNSRule 2.10 and TVR
12th May 20081:49 pmRNSAdditional Listing
9th May 20088:48 amRNSOffer Rejection
9th May 20088:37 amRNSOffer for Flomerics Group plc
30th Apr 20084:23 pmRNSHolding(s) in Company
30th Apr 200811:14 amRNSAdditional Listing
29th Apr 20087:01 amRNSFinal Results
18th Apr 200812:06 pmRNSAdditional Listing
15th Apr 200810:41 amRNSDirectorate Change
10th Apr 20082:51 pmRNSHolding(s) in Company
10th Apr 20087:00 amRNSTotal Voting Rights
27th Mar 20087:02 amRNSUpdate
19th Mar 200812:58 pmRNSHolding(s) in Company
19th Mar 200810:11 amRNSHolding(s) in Company
18th Mar 20083:59 pmRNSAdditional Listing
18th Mar 20087:30 amRNSHolding(s) in Company
17th Mar 200811:27 amRNSHolding(s) in Company
14th Mar 20083:17 pmRNSHolding(s) in Company
3rd Mar 20087:00 amRNSAdditional Listing
28th Feb 20082:37 pmRNSDirector/PDMR Shareholding
27th Feb 200810:50 amRNSDirector/PDMR Shareholding
22nd Feb 20085:31 pmRNSDirector/PDMR Shareholding
21st Feb 200812:19 pmRNSGrant of Options
9th Jan 20087:00 amRNSTrading Statement
20th Dec 20077:02 amRNSDisposal
19th Dec 200712:36 pmRNSHolding(s) in Company
3rd Dec 200712:00 pmRNSDirectorate Change
27th Sep 200711:23 amRNSAdditional Listing
27th Sep 20079:41 amRNSHolding(s) in Company
19th Sep 20077:02 amRNSInterim Results
14th Sep 20075:03 pmRNSHolding(s) in Company
15th Aug 20072:27 pmRNSAIM Rule 26
13th Jul 20077:00 amRNSTrading Statement
12th Jul 20075:07 pmRNSHolding(s) in Company
5th Jul 200711:41 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.